Transcript Lipidomic
Proteomic, Metabolomic and Lipidomic Research Capability at ICH and ION Lipidomics UCL UCL Proteomic, Metabolomic and Lipidomic Research Capability at ICH and ION • Same principle as the proteomic mass spectral method • Urine/plasma/CSF injected into a UPLC QTOF mass spectrometer lipids separated by UPC2 chromatography (supercritical fluid chromatography) Uses CO2 to separate lipids out according to their polar properties not non-polar (reverse phase) Lipids are easier to identify than metabolites as they have been more extensively studied FFA Mix 1 FFA Method 0.5ul inj 15CV0 C22 17:14:13 TAGs_08022012_026 100 C20 C18 C16 C14 03-Aug-2012 1: TOF MS ESBPI 1.71e5 1.72 339.3196 1.52 311.2894 C24 1.35 283.2587 1.93 367.3502 1.18 255.2276 1.05 227.1970 % Free fatty acids C12 0.91 199.1659 C10 0.79 171.1348 C8 0 Time 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 Proteomic, Metabolomic and Lipidomic Research Capability at ICH and ION • Same principle as the proteomic mass spectral method • Urine/plasma/CSF injected into a UPLC QTOF mass spectrometer UCL lipids separated by UPC2 chromatography (supercritical fluid chromatography) Uses CO2 to separate lipids out according to their polar properties not non-polar (reverse phase) Lipids are easier to identify than metabolites as they have been more extensively studied Triacylglycerols Chosteryl esters ( Mixture of FFA, TAG, and CE UCL Proteomic, Metabolomic and Lipidomic Research Capability at ICH and ION • Phospholipid analyses from human heart C34:0 8x107 Phosphatidylcholine 6x107 In te n s ity C32:0 C36:0 C30:1 Phosphatidylethanolamine 4x107 Sphingomyelin C36:1 ceramides Phosphatidylcholine Lyso-phosphatidylethanolamine C36:3 Lyso C38:3phosphatidyl choline 2x107 Phosphatidylglycerol 0 0.50 1.00 1.50 2.00 2.50 Minutes 3.00 3.50 4.00 4.50